MedTrace Logo

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

NCT06714383 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-12-03

No results posted yet for this study

Summary

To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.

Conditions

Interventions

DRUG

Trilaciclib

Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.

DRUG

Pirarubicin

Pirarubicin: 60 mg/m2，IV，d1-2

DRUG

Lobaplatin

LobaplLatin: 40 mg/m2,，IV，d1

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2025-07-31
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06714383 on ClinicalTrials.gov